204 related articles for article (PubMed ID: 37864894)
21. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
22. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
23. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
24. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
25. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
26. Induction of cell death in human macrophages by a highly virulent Korean Isolate of Mycobacterium tuberculosis and the virulent strain H37Rv.
Sohn H; Lee KS; Kim SY; Shin DM; Shin SJ; Jo EK; Park JK; Kim HJ
Scand J Immunol; 2009 Jan; 69(1):43-50. PubMed ID: 19140876
[TBL] [Abstract][Full Text] [Related]
27. Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins.
Kump KJ; Miao L; Mady ASA; Ansari NH; Shrestha UK; Yang Y; Pal M; Liao C; Perdih A; Abulwerdi FA; Chinnaswamy K; Meagher JL; Carlson JM; Khanna M; Stuckey JA; Nikolovska-Coleska Z
J Med Chem; 2020 Mar; 63(5):2489-2510. PubMed ID: 31971799
[TBL] [Abstract][Full Text] [Related]
28. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
[TBL] [Abstract][Full Text] [Related]
30. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages.
Chen D; Ma S; He L; Yuan P; She Z; Lu Y
Tuberculosis (Edinb); 2017 Mar; 103():37-43. PubMed ID: 28237032
[TBL] [Abstract][Full Text] [Related]
31. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
32. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
Sarif Z; Tolksdorf B; Fechner H; Eberle J
Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
[TBL] [Abstract][Full Text] [Related]
33. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
34. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
35. Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy.
He W; Li X; Morsch M; Ismail M; Liu Y; Rehman FU; Zhang D; Wang Y; Zheng M; Chung R; Zou Y; Shi B
ACS Nano; 2022 Apr; 16(4):6293-6308. PubMed ID: 35353498
[TBL] [Abstract][Full Text] [Related]
36. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R
Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828
[TBL] [Abstract][Full Text] [Related]
37. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
Martins M
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742
[TBL] [Abstract][Full Text] [Related]
38. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
39. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
Fatima S; Bhaskar A; Dwivedi VP
Front Immunol; 2021; 12():645485. PubMed ID: 33927718
[TBL] [Abstract][Full Text] [Related]
40. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis.
Nguyen PC; Delorme V; Bénarouche A; Guy A; Landry V; Audebert S; Pophillat M; Camoin L; Crauste C; Galano JM; Durand T; Brodin P; Canaan S; Cavalier JF
Bioorg Chem; 2018 Dec; 81():414-424. PubMed ID: 30212765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
